tetano
Editor, Senior Moderator
Zhonghua Zhong Liu Za Zhi. 2020 Mar 5;42(0):E008. doi: 10.3760/cma.j.cn112152-20200303-00166. [Epub ahead of print] [h=1][The differential diagnosis of pulmonary infiltrates in cancer patients during the outbreak of the 2019 novel coronavirus disease].[/h]
[Article in Chinese; Abstract available in Chinese from the publisher]
Zhu WJ[SUP]1[/SUP], Wang J[SUP]2[/SUP], He XH[SUP]2[/SUP], Qin Y[SUP]2[/SUP], Yang S[SUP]2[/SUP], Hu XS[SUP]2[/SUP], Wang HY[SUP]2[/SUP], Huang J[SUP]2[/SUP], Zhou AP[SUP]2[/SUP], Ma F[SUP]2[/SUP], Shi YK[SUP]2[/SUP], Zhou SY[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] in English, Chinese
Objective: To investigate the principles of differential diagnosis of pulmonary infiltrates in cancer patients during the outbreak of novel coronavirus (2019-nCoV) by analyzing one case of lymphoma who presented pulmonary ground-glass opacities (GGO) after courses of chemotherapy. Methods: Baseline demographics and clinicopathological data of eligible patients were retrieved from medical records. Information of clinical manifestations, history of epidemiology, lab tests and chest CT scan images of visiting patients from February 13 to February 28 were collected. Literatures about pulmonary infiltrates in cancer patients were searched from databases including PUBMED, EMBASE and CNKI. Results: Among the 139 cancer patients underwent chest CT scans before chemotherapy, pulmonary infiltrates were identified in eight patients (5.8%), five of whom were characterized as GGOs in lungs. 2019-nCoV nuclear acid testing was performed in three patients and the results were negative. One case was a 66-year-old man diagnosed as non-Hodgkin lymphoma and underwent CHOP chemotherapy regimen. His chest CT scan image displayed multiple GGOs in lungs and the complete blood count showed decreased lymphocytes. This patient denied any contact with confirmed/suspected cases of 2019-nCoV infection and without fever and other respiratory symptoms. Considering the negative result of nuclear acid testing, this patient was presumptively diagnosed as viral pneumonia and an experiential anti-infection treatment had been prescribed for him. Conclusions: The 2019 novel coronavirus disease (COVID-19) complicates the clinical scenario of pulmonary infiltrates in cancer patients. The epidemic history, clinical manifestation, CT scan image and lab test should be combined consideration. The 2019-nCoV nuclear acid testing might be applicated in more selected patients. Active anti-infection treatment and surveillance of patient condition should be initiated if infectious disease is considered.
[h=4]KEYWORDS:[/h] COVID-19; Drug-induced pulmonary injury; Neoplasm; Pulmonary infiltrates; Viral pneumonia
PMID: 32133833 DOI: 10.3760/cma.j.cn112152-20200303-00166
[Article in Chinese; Abstract available in Chinese from the publisher]
Zhu WJ[SUP]1[/SUP], Wang J[SUP]2[/SUP], He XH[SUP]2[/SUP], Qin Y[SUP]2[/SUP], Yang S[SUP]2[/SUP], Hu XS[SUP]2[/SUP], Wang HY[SUP]2[/SUP], Huang J[SUP]2[/SUP], Zhou AP[SUP]2[/SUP], Ma F[SUP]2[/SUP], Shi YK[SUP]2[/SUP], Zhou SY[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] in English, Chinese
Objective: To investigate the principles of differential diagnosis of pulmonary infiltrates in cancer patients during the outbreak of novel coronavirus (2019-nCoV) by analyzing one case of lymphoma who presented pulmonary ground-glass opacities (GGO) after courses of chemotherapy. Methods: Baseline demographics and clinicopathological data of eligible patients were retrieved from medical records. Information of clinical manifestations, history of epidemiology, lab tests and chest CT scan images of visiting patients from February 13 to February 28 were collected. Literatures about pulmonary infiltrates in cancer patients were searched from databases including PUBMED, EMBASE and CNKI. Results: Among the 139 cancer patients underwent chest CT scans before chemotherapy, pulmonary infiltrates were identified in eight patients (5.8%), five of whom were characterized as GGOs in lungs. 2019-nCoV nuclear acid testing was performed in three patients and the results were negative. One case was a 66-year-old man diagnosed as non-Hodgkin lymphoma and underwent CHOP chemotherapy regimen. His chest CT scan image displayed multiple GGOs in lungs and the complete blood count showed decreased lymphocytes. This patient denied any contact with confirmed/suspected cases of 2019-nCoV infection and without fever and other respiratory symptoms. Considering the negative result of nuclear acid testing, this patient was presumptively diagnosed as viral pneumonia and an experiential anti-infection treatment had been prescribed for him. Conclusions: The 2019 novel coronavirus disease (COVID-19) complicates the clinical scenario of pulmonary infiltrates in cancer patients. The epidemic history, clinical manifestation, CT scan image and lab test should be combined consideration. The 2019-nCoV nuclear acid testing might be applicated in more selected patients. Active anti-infection treatment and surveillance of patient condition should be initiated if infectious disease is considered.
[h=4]KEYWORDS:[/h] COVID-19; Drug-induced pulmonary injury; Neoplasm; Pulmonary infiltrates; Viral pneumonia
PMID: 32133833 DOI: 10.3760/cma.j.cn112152-20200303-00166